drugset / Trial / NCT01348126

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer

NCT01348126

Phase 2/3 Terminated 385 enrolled Synta Pharmaceuticals Corp.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.

Timeline

Start
2011-05
Primary completion
2014-04
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Docetaxel Small molecule 75 mg/m2 Intravenous
Subject Ganetespib Small molecule 150 mg/m2 Intravenous